GYPA
Glycophorin-A
Also known as: CD235a, GLPA_HUMAN, GPA, MN, MNS
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P02724
- Gene
- GYPA
- Ensembl
- ENSG00000170180
- Chromosome
- 4
- Canonical length
- 150 aa
- Protein class
- Blood group antigen proteins, CD markers, Predicted membrane proteins, Transporters
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Glycophorins A (GYPA) and B (GYPB) are major sialoglycoproteins of the human erythrocyte membrane which bear the antigenic determinants for the MN and Ss blood groups. In addition to the M or N and S or s antigens that commonly occur in all populations, about 40 related variant phenotypes have been identified. These variants include all the variants of the Miltenberger complex and several isoforms of Sta, as well as Dantu, Sat, He, Mg, and deletion variants Ena, S-s-U- and Mk. Most of the variants are the result of gene recombinations between GYPA and GYPB. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
150 residues, UniProt reviewed canonical sequence.
>P02724|GYPA
1 MYGKIIFVLL LSEIVSISAL STTEVAMHTS TSSSVTKSYI SSQTNDTHKR DTYAATPRAH
61 EVSEISVRTV YPPEEETGER VQLAHHFSEP EITLIIFGVM AGVIGTILLI SYGIRRLIKK
121 SPSDVKPLPS PDTDVPLSSV EIENPETSDQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GYPA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.63
- Highest tissue expression
- 147 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 147 nTPM
- placenta: 3.8 nTPM
- spleen: 2.3 nTPM
- kidney: 2.2 nTPM
- liver: 0.5 nTPM
- lung: 0.4 nTPM
Single-cell type
- erythrocyte progenitors: 235 nCPM
- erythrocytes: 111 nCPM
- proximal tubule cells: 4.8 nCPM
- epicardial cells: 2.3 nCPM
- brain inhibitory neurons: 2 nCPM
- brain excitatory neurons: 1.7 nCPM
Immune cell
- naive B-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebral cortex: 12 nTPM
- white matter: 7.7 nTPM
- basal ganglia: 7.3 nTPM
- amygdala: 5.7 nTPM
- pons: 5.2 nTPM
- thalamus: 4.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GYPA.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 21 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- BLOOD GROUP ERIK
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.16
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.55
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GYPA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GYPA as an antibody target. Whether an autoantibody or antibody against GYPA could matter depends on whether native GYPA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GYPA is annotated at the cell surface, where native GYPA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GYPA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...